CUTAQUIG

Phase 3Small molecule

Octapharma

CUTAQUIG is one of 55 small molecule programs targeting Immunodeficiency Disease. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Immunodeficiency DiseaseActive, not recruiting

ImmunodeficiencyActive, not recruiting

Immunodeficiency DiseasePhase 3

Active, not recruiting

ImmunodeficiencyPreclinical

Active, not recruiting

Competition

Competitive Landscape

296 competitors in Immunodeficiency

#DrugCompanyPhaseTrials

Retrovir

BBp Consulting, Inc

Phase 3

6 2

Truvada

Gilead

Phase 3

2 3

Prevnar 13

Merck & Co.

Phase 3

2 4

CAB LA

GSK

Phase 3

5 5

V114

Merck & Co.

Phase 3

2 6

B/F/TAF

Gilead

Phase 3

7 7

FTC/TDF

Gilead

Phase 3

1 8

Immunoglobulin G

CSL Behring

Phase 3

1 9

Biktarvy

GSK

Phase 3

1 10

DTG/3TC

GSK

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Immunodeficiency Disease1 trial

Study to Monitor Subcutaneous Human Immunoglobulin Administered at Modified Dosing Regimens in Patients With Primary Immunodeficiency Diseases

Completed· Octapharma logo

Octapharma·Phase 3·NCT03939533·64 enrolled

Primary Immunodeficiencies1 trial

Evaluation of Subcutaneous Immunoglobulin Product Cutaquig in Terms of Safety and Efficacy in the Treatment of Patients With Primary Immunodeficiencies

Unknown status·FFederal Research Institute of Pediatric Hematology, Oncology and Immunology··NCT05986734·100 enrolled

Immunodeficiency1 trial

Observational Study of Subcutaneous Immunoglobulin (Cutaquig) in Patients With Primary and Secondary Immunodeficiency.

Active, not recruiting·UUniversity of Alberta··NCT04354129·36 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for CUTAQUIG. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — CUTAQUIG compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for CUTAQUIG. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Octapharma company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Octapharma

CUTAQUIG

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Immunodeficiency Disease1 trial

Primary Immunodeficiencies1 trial

Immunodeficiency1 trial

References

Drug Info

Quick Facts

Related News